Iovance Biotherapeutics Stock Earnings Reports

Iovance reported strong commercial and operational momentum in Q1 2026. Total revenue rose ~45% year-over-year to $71M, driven by Amtagvi ($60M) and Proleukin ($11M). Management guided Q2 revenue of $86M–$88M (Amtagvi $79M–$81M) and full-year 2026 revenue of $350M–$370M, citing all-time-high enrollment/referral trends and improving demand. The company completed maintenance upgrades and shifted Amtagvi manufacturing fully in-house at its iCTC, which management says will enable scale, uninterrupted supply and improving gross margins (Q1 gross margin ~41% impacted by one-time costs). R&D expense declined for the third consecutive quarter, helping extend cash runway; the company reported ~$319M in cash and expects to fund operations into 2028. Pipeline progress: compelling early Phase II data in metastatic serous endometrial cancer (40% confirmed ORR, 100% disease control in first five patients) with plans to engage FDA for expedited pathway; Fast Track designation in previously treated non-squamous NSCLC with durable responses and an expected clinical update this year targeting accelerated approval and potential U.S. launch in H2 2027; a registrational sarcoma trial (IOV-SAR-201) starting enrollment in Q3 2026 after promising early data; and advancement of next-generation programs IOV-5001 (IL-12-tethered TIL; IND submitted), IOV-3001 (next-gen IL-2) and IOV-4001 (PD-1-inactivated TIL). Commercial execution highlights include expansion of ATC network (academic + community centers), growing physician awareness (70% vs 50% six months ago), stronger field sales, and ongoing ex-U.S. regulatory/reimbursement efforts (Canada approval in hand; Australia and Switzerland progressing). Management emphasized financial discipline, operational efficiencies, and a clear path toward profitability with a long-term peak sales thesis (> $1B in the U.S. for Amtagvi + Proleukin).